Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Curr Microbiol. 2024 Sep 29;81(11):383. doi: 10.1007/s00284-024-03824-4.
Brucella is a facultative intracellular gram-negative coccobacillus. It is nonsporulating and reproduced in macrophage phagosomes. The use of nanostructures as drug and vaccine carriers has recently received attention due to their ability to control the release profile and protect the drug molecules. This study presents a suitable nano-polyethyleneimine formulation to be used as an immunoadjuvant and LPS along with trivalent candidate antigens of TF, BP26, and omp31 to selectively stimulate the immune response. After designing and evaluating the immunogenic structure by databases and bioinformatics software, recombinant protein cloning and gene expression were performed in Escherichia coli BL21 bacteria. This protein was extracted from the cultured cells, purified by Ni-NTA column. After placing the antigen inside the polyethyleneimine nanostructure, various properties of the nanoparticles, including their size, zeta potential, and retention rate for injection and inhalation of mice, diffusion efficacy, and antigen binding evaluation were evaluated. Mice were treated with different groups of antigens and nanoparticles on days 0, 10, 24, and 38. Two weeks after the last injection, the level of cytokines were investigated in spleen cells, including IFN-γ, IL-4, and IL-12. The serum concentration of IgG2a and IgG1 antibodies were also assessed. The response was consistent with significant production of IgG1, IgG2a, IFN-γ21, IL-12, and IL-4 compared to the controls (P < 0.05). Compared to the positive and negative control groups, recombinant protein and nanoparticles showed a good response in subsequent injections with live bacterial strains. The present study also revealed the potential of the developed recombinant protein as a candidate in the design and manufacture of subunit vaccines against Brucella species. This protein stimulates cellular and humoral immune responses compared to the positive control groups. These findings can be useful in the prevention and control of brucellosis and pave the way for further research by researchers around the world.
布鲁氏菌是一种兼性细胞内革兰氏阴性球杆菌。它是非孢子形成的,在巨噬细胞吞噬体中繁殖。由于纳米结构能够控制药物的释放特性并保护药物分子,因此最近它们作为药物和疫苗载体受到了关注。本研究提出了一种合适的纳米聚亚胺配方,可作为免疫佐剂与 LPS 以及 TF、BP26 和 omp31 三价候选抗原一起使用,以选择性地刺激免疫反应。在通过数据库和生物信息学软件设计和评估免疫原性结构后,在大肠杆菌 BL21 细菌中进行了重组蛋白的克隆和基因表达。从培养的细胞中提取该蛋白,并用 Ni-NTA 柱进行纯化。将抗原放入聚乙烯亚胺纳米结构内后,评估了纳米粒子的各种性质,包括其大小、zeta 电位、在注射和吸入小鼠体内的保留率、扩散效果和抗原结合评估。用不同的抗原和纳米粒子处理组在第 0、10、24 和 38 天对小鼠进行处理。最后一次注射后两周,研究了脾细胞中细胞因子的水平,包括 IFN-γ、IL-4 和 IL-12。还评估了血清 IgG2a 和 IgG1 抗体的浓度。与对照组相比,该反应与 IgG1、IgG2a、IFN-γ21、IL-12 和 IL-4 的显著产生一致(P<0.05)。与阳性和阴性对照组相比,重组蛋白和纳米粒子在随后的活菌株注射中表现出良好的反应。本研究还揭示了所开发的重组蛋白作为布鲁氏菌属亚单位疫苗设计和制造的候选物的潜力。与阳性对照组相比,该蛋白刺激细胞和体液免疫反应。这些发现对于布鲁氏菌病的预防和控制可能有用,并为世界各地的研究人员开辟了进一步研究的道路。